With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
VTRS — frequently asked questions
Is Viatris Inc. overvalued?
In our latest published analysis dated 2026-10-10, VTRS screens modestly overvalued. The price recorded at analysis is USD 17.6 versus our fair value of USD 15.9; the high endpoint is presented separately as potential value of USD 18.8. That implies roughly 9.8% downside to fair value at that date.
Our latest published report, analyzed 2026-10-10, gives VTRS a fair value of USD 15.9 and a potential value of USD 18.8. The conclusion is triangulated across multiple valuation models and weighted by reliability for Viatris Inc.'s archetype; it is a dated research output, not a live price.
Should I buy VTRS now?
Our latest published rating for VTRS, analyzed 2026-10-10, is Reduce. Viatris Inc. screens modestly overvalued at the analysis-date price of USD 17.6 versus fair value of USD 15.9; potential value is USD 18.8. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for VTRS?
The dedicated bear-case section in our report analyzed 2026-10-10 documents Viatris Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is VTRS's rating?
Our latest published rating for VTRS, analyzed 2026-10-10, is Reduce, with a published moat assessment of 5.5/10 (Narrow). It reflects our fair value of USD 15.9, the potential value of USD 18.8, and the price recorded at analysis (USD 17.6).
Accelerated regulatory approval and successful commercial launch of proprietary specialty assets, particularly non-opioid meloxicam with up to $500M peak sales potential and multi-year exclusivity, alongside complex biosimilars expanding gross margins above 38%.
Main risk
Persistent generic pricing concessions demanded by consolidated wholesale distributors (Cencora 11%, McKesson 10%, Cardinal Health 5%) combined with prolonged supply disruption from the Nashik manufacturing facility.
Viatris Inc. trades at $17.64, representing a 10.87% premium to our Fair value of $15.91. Although free cash flow of $1.94B supports ongoing capital returns, substantial leverage of $14.70B and a high cost of capital of 13.04% justify a Reduce rating.1,3
Viatris operates an extensive global pharmaceutical commercialization and manufacturing platform, generating $14,250.4M in consolidated revenue in FY2025. The business is anchored by its Developed Markets segment, which contributed $8,514.0M (59.7% of sales), and supplemented by high-margin legacy branded lines in Greater China contributing $2,332.5M. Operating cash flow generation remained robust at $2,315.9M in FY2025, translating into $1,937.1M in free cash flow that comfortably funded $561.2M in shareholder dividends and $500.5M in share buybacks while leaving surplus capital for debt repayment.5,6
However, the stock trades at an implied return of -9.81% relative to our Fair value of $15.91. While management raised guidance midpoints for FY2026, projecting ~2% operational revenue growth and 7% adjusted EPS growth, the company remains burdened by $14,701.4M in total debt. In an environment where computed WACC stands at 13.0448% driven by a 19.76% pre-tax cost of debt, capital structure costs absorb substantial operating value. Combined with wholesale distributor concentration and temporary supply disruptions at the Nashik facility, risk-adjusted returns warrant a defensive stance.1,3,4
Viatris generates approximately $1.94B in annual free cash flow, providing robust coverage for its $0.48 per share dividend distribution and share repurchases.
High-Volume Regulatory Approvals and Complex Generic Pipeline
The company secured 70 approvals in 1H 2026 and tracks over 100 full-year product approvals, with late-stage pipeline opportunities including non-opioid meloxicam offering up to $500M in peak sales potential.4
Broad Global Commercial Footprint
Developed Markets anchor $8,514.0M in sales while Greater China contributes $2,332.5M, providing global commercial reach across retail and hospital networks.6
House recommendation
Reduce. At $17.64, shares trade at a premium to our $15.91 Fair value. Investors should trim positions on strength toward the upper end of the fair value range and avoid new capital allocation until balance sheet leverage is reduced.3
Company overview
Viatris Inc. is a global healthcare company formed through the combination of Mylan and Upjohn (a legacy division of Pfizer). The company provides a diversified portfolio encompassing standard generic medicines, complex generic formulations, biosimilars, and established off-patent branded pharmaceuticals across therapeutic areas including cardiovascular, central nervous system, immunology, infectious disease, and pain management.
The company operates across four distinct geographic reporting segments: Developed Markets, Greater China, Emerging Markets, and JANZ (Japan, Australia, and New Zealand). Viatris serves retail pharmacies, hospital systems, government healthcare agencies, and wholesale distributors globally.
In a combined stress scenario where distributor consolidation drives operating margin down 300 bps and debt refinancing increases WACC by 200 bps toward 15.0%, free cash flow available for debt service contracts sharply. Carrying $14.70B in total debt under elevated interest rates would consume operational cash flow, halting share repurchases and forcing dividend reductions. In our supporting enterprise valuation, cash flow discounting under a 13.0448% WACC already results in an equity value of $3.45 per share, demonstrating extreme sensitivity to refinancing spreads and margin contraction.
Viatris maintains a Narrow economic moat supported by its extensive global manufacturing footprint, deep regulatory filing capabilities, and established commercial relationships across developed and emerging healthcare markets. The company's platform scale enables it to navigate multi-jurisdictional regulatory frameworks and secure over 100 new product approvals annually, having achieved 70 approvals in the first half of 2026 alone. This continuous replenishment is essential for defending gross margins against annual low-single-digit price deflation inherent in off-patent pharmaceuticals.
The moat is further reinforced by brand recognition in international markets. In Greater China, where Viatris generated $2,332.5M in FY2025 revenue, mature branded medications enjoy strong physician and patient preference in retail out-of-pocket pharmacy channels, partially insulating the portfolio from centralized volume-based procurement price cuts. Similarly, Developed Markets generated $8,514.0M in FY2025, providing essential volume scale across institutional and retail dispensing channels.
Nonetheless, structural limitations prevent Viatris from commanding a Wide economic moat. The company faces high wholesale buyer concentration, with Cencora accounting for 11% of in FY2025, alongside McKesson at 10% and Cardinal Health at 5%. This buying power, coupled with manufacturing compliance vulnerabilities such as the Nashik facility disruption, places ongoing pressure on return on capital and caps .
The highlighted cell is Fair value when every assumption sits at its base level ($15.91). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $1.7B after modeled reinvestment of $365.8M, with terminal value at 62.6% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Upgrade the rating; Evaluate the sustainability of operating margin expansion and monitor debt reduction pace without altering overall portfolio stance.
Trigger: Reported revenue and earnings exceeding consensus projections, with operating margins expanding and order fulfillment normalizing across manufacturing facilities.
An earnings beat driven by operational margin expansion and complex generic acceleration would improve debt service coverage and narrow the gap to Fair value.
In-line
Maintain Reduce; Maintain reduced exposure and track quarterly cash conversion ratios and debt retirement progress.
Trigger: Reported revenue and earnings matching , with and tracking full-year .
Industry capex-to-revenue stands at 1.1% and capex-to-depreciation is 0.8 as of 2026-10-05, indicating capital contraction and disciplined asset reinvestment across mature pharmaceuticals. Viatris's FY2025 capital expenditures were $378.8M (~2.66% of sales) against depreciation of $2,798.3M.
Bull cycle
A generic and specialty pharmaceutical bull cycle features expanding global prescription volume driven by aging demographics, rapid regulatory approval and commercialization of complex biosimilars and specialty injectables, and stable hospital demand. Growing middle-class healthcare spending in emerging markets supports premium pricing for established off-patent branded medicines in retail channels.
Bear cycle
A generic pharmaceutical bear cycle is characterized by accelerating distributor and buying consortium consolidation, aggressive price erosion on commoditized oral solids, government-mandated centralized procurement price cuts such as China's VBP tenders, and regulatory compliance enforcement leading to facility remediation downtime.
§11 Position management
Sizing
0-1%
Given the house Reduce rating and a 10.87% premium to Fair value of $15.91, investors should maintain a minimal or zero portfolio weight, trimming exposure on strength.3
Risk
Risk management requires limiting exposure to heavily leveraged healthcare compounders during periods of elevated interest rates. With total debt of $14.70B and a computed WACC of 13.0448%, equity value is highly sensitive to credit spread widening and operational disruptions. Position size should be kept strictly underweight.
The $0.48 annual dividend per share is supported by $1.94B in annual free cash flow; existing income investors may hold for yield, but should be aware of debt refinancing risks.
Value / Deep Value
Avoid
Although forward P/E of 6.38x appears optically cheap, enterprise yields only $3.45 per share after deducting $14.70B of total debt.
§14 Final recommendation
Action
Reduce
We recommend a Reduce rating on Viatris Inc. At the October 9, 2026 price of $17.64, the stock trades at an implied return of -9.81% and a 10.87% premium to intrinsic value.3
While Viatris generates approximately $1.94B in annual free cash flow and maintains strong commercial presence across Developed Markets ($8.51B revenue) and Greater China ($2.33B), its $14.70B debt burden and a 13.04% WACC severely constrain equity accretion.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Operating margin contracts substantially below baseline due to distributor purchasing power
Manufacturing outages at Nashik persist, reducing annual revenue growth
Debt refinancing costs increase corporate cost of capital
Under the Bear scenario, generic price deflation accelerates due to distributor consolidation, while prolonged manufacturing outages reduce order fulfillment. Operating margins contract and refinancing maturing debt at elevated interest rates consumes operating cash flow, impairing equity value.
Ways this thesis can break
Severe generic price erosion and distributor consolidation drive operating margin down by 300 bps across Developed Markets and China.
Customer concentration with Cencora accounting for 11% of revenue combined with distributor concentration among McKesson (10%) and Cardinal Health (5%) accelerates generic pricing concessions. Management flagged competitive pressure on Dymista and lower-margin products, compressing operating margins below baseline expectations.4,6
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Prolonged manufacturing outages at the Nashik facility persist through FY2027, reducing annual revenue growth by 5 percentage points.
Manufacturing disruptions following the Q1 fire and FDA May inspection at the Nashik plant create a $100M-$150M revenue headwind in 2H 2026. If remediation stalls and regulatory compliance issues spread across sterile injectables or oral solid dose lines, order fulfillment rates (currently ~70%) fail to recover, cutting multi-year revenue growth.4
FV impact
-6%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 18 months
Terminal P/E multiple contracts by 20% to 6.0x as market prices persistent generic commoditization and high financial leverage.
Viatris trades at a forward P/E of 6.38x and carries $14.70B in total debt. Elevated leverage and substantial annual debt service obligations constrain cash conversion and heighten financial vulnerability. Under prolonged balance sheet stress and high debt service, equity multiple expansion to 7.5x will fail to materialize, re-rating terminal multiples lower.3
Weighted average cost of capital increases by 200 bps as $14.7B in legacy debt matures and requires refinancing at elevated interest rates.
Viatris carries $14.70B in total debt with computed WACC already at 13.0448%. Significant legacy debt maturities and vulnerable cash conversion amplify balance sheet fragility during refinancing periods. A 200 bps increase in cost of debt and capital sharply reduces equity value in debt-heavy enterprise models.1,3
FV impact
-7.4%
Cost of capital 2 points higher
Trigger
Within 36 months
Early-warning signals to monitor
The five developments that would weaken our investment case.
Net debt to EBITDA exceeding 3.5x or failing to pay down at least $1B of gross debt annually signals capital misallocation and raises refinancing costs under a 13.04% WACC.
On an operating cash flow basis, Viatris generates approximately $1.94B in annual free cash flow, covering normalized capital costs. However, reported GAAP ROIC is distorted by large non-cash goodwill and intangible impairment write-downs totaling -$3,514.9M in net income for FY2025. Enterprise-level economic profit remains constrained by an elevated WACC of 13.0448% reflecting a 19.76% pre-tax cost of debt on $14.70B of total debt.1,3
5.5/ 10
Narrow
Sources of advantage
01Regulatory Scale and Complex Manufacturing Platform — Viatris secured 70 new product approvals in the first half of 2026 and remains on track for more than 100 approvals for the full year. Its technical depth in complex generics, biosimilars, and specialty delivery formulations creates regulatory hurdles that generic oral solid commoditizers cannot easily surmount.Moderate
02Global Commercial Distribution and Established Brand Equity — In Developed Markets, Viatris generated $8,514.0M in FY2025 revenue, while Greater China delivered $2,332.5M. Established brand recognition for off-patent legacy medications sustains out-of-pocket consumer loyalty and hospital re-order volumes despite patent expiration.Moderate
The Bull case envisions accelerated commercialization of complex generics and specialty pipeline assets, such as meloxicam reaching peak sales potential up to $500M. Operating margins expand substantially and rapid deleveraging drives multiple re-rating toward peer levels.4
Meeting baseline consensus confirms that current trading at $17.64 already reflects operating cash flows while debt leverage continues to constrain Fair value at $15.91.
Miss
Downgrade the rating; Reassess balance sheet liquidity, check credit covenants, and accelerate capital preservation by curtailing remaining exposure.
Trigger: Reported results falling short of consensus expectations due to deeper generic pricing concessions, extended facility downtime, or contracting operating margins.
An operational miss would impair free cash flow conversion, slowing balance sheet deleveraging and widening downside toward Fair value.
Earnings quality reflects a significant contrast between GAAP reported net income and underlying operating cash flow. Non-cash goodwill and intangible asset impairments have generated large accounting net losses, whereas normalized operational cash generation from Developed Markets and international commercial divisions remains positive. Operating earnings reflect substantial non-cash depreciation and amortization expenses relative to modest maintenance capital expenditure requirements. Working capital needs remain manageable, but high debt service burdens absorb a large portion of operational cash generation.
Estimate momentum
Analyst consensusearnings estimates have remained essentially flat following the recent quarterly release. While management raised full-year guidance midpoints across key metrics on solid first-half operating leverage, revisions to top-line projections have been tempered by temporary manufacturing supply constraints in the second half. Overall estimate dispersion remains narrow across covering sell-side analysts.
Metrics to watch into the print
01
Metric:
Manufacturing Facility Remediation and Order Fulfillment Recovery
CurrentManagement reports intermittent disruption following facility inspections, with order fulfillment tracking below full capacity.
Why it matters
Restoring order fulfillment across sterile injectables and oral dose lines is critical to reversing recent supply headwinds.
02
Metric:
Complex Generic and Biosimilar Regulatory Approvals
CurrentApprovals are tracking ahead of schedule, with the majority of planned annual approvals already secured in the first half.
Why it matters
New product approvals provide the primary offset to standard generic pricing deflation in developed markets.
Cash flow generation remains the central financial strength of Viatris. Despite reporting a GAAP net loss of -$3,514.9M in FY2025 due to non-cash goodwill and intangible asset impairments, the company produced $2,315.9M in operating cash flow and $1,937.1M in free cash flow. This represents an FCF conversion rate exceeding 80% of operating cash flow. In the first half of 2026, revenue of $7,255.6M and gross profit of $2,613.7M confirmed operational stability. However, debt servicing requirements under a 13.0448% WACC absorb a substantial share of cash flow.1,3
Viatris prioritizes capital allocation toward balance sheet deleveraging, dividend distributions, and opportunistic share repurchases. In FY2025, operating cash flow of $2,315.9M and free cash flow of $1,937.1M fully funded $561.2M in cash dividends ($0.48/share) and $500.5M in share buybacks, leaving approximately $875M for net debt retirement against total debt of $14,701.4M. Capital expenditures were kept restrained at $378.8M (2.66% of sales). In the first half of 2026, long-term debt was reduced to $11,612.4M as of June 30, 2026.
On an operational cash basis, Viatris generates approximately $1.94B in annual free cash flow, sustaining consistent debt reduction and capital returns. Accounting ROIC remains depressed by non-cash intangible asset write-downs. As legacy debt is gradually paid down and operating margins normalize toward 18.5%, operational cash return on capital is expected to remain stable.
The company's computed WACC of 13.0448% exceeds reported accounting returns, driven by a 19.76% pre-tax cost of debt on $14.70B of total debt. This spread creates an economic profit deficit until debt retirement reduces capital structure drag.
GAAP Accounting Loss Masks Robust Multi-Billion Free Cash Flow
GAAP earnings measures are distorted by legacy non-cash impairment charges; evaluating intrinsic value requires anchoring on normalized operating profitability and cash conversion.
Developed Markets Anchor Cash Generation While China Faces Procurement Deflation
Developed Markets generated $8,514.0M in FY2025, while Greater China contributed $2,332.5M, where VBP pricing headwinds were noted.
Cash flow stability depends predominantly on prescription refill volumes in Developed Markets offsetting persistent single-digit price deflation across standard off-patent lines.
High Financial Leverage and Capital Costs Severely Restrict Equity Value
Viatris carries $14,701.4M in total debt with a computed WACC of 13.0448% and a pre-tax cost of debt of 19.76%.
In our supporting enterprise DCF model, subtracting $14.70B in debt yields an equity value of $3.45 per share, demonstrating that debt obligations heavily dilute equity claims.
Viatris Inc. (VTRS) trades at 6.4x forward earnings against a peer median of 12.2x. Its EV/EBITDA of 7.5x compares with a peer median of 10.5x. The comparison uses 4 peers: Centene Corporation, Baxter International Inc., Charles River Laboratories International Inc. and Moderna Inc., as of 2026-10-08 to 2026-10-10.
Secular trends
Trend
Impact
Note
Global Demographic Aging and Chronic Disease Prevalence
positive
Aging populations across North America, Europe, and Asia drive non-discretionary baseline prescription demand for chronic cardiovascular, metabolic, and pain therapies.
The top three wholesale distributors in North America—Cencora (11% share), McKesson (10%), and Cardinal Health (5%)—exert aggressive pricing pressure on generic suppliers.
Centralized Government Healthcare Cost Containment
negative
Centralized volume-based procurement (VBP) rounds in international markets systematically cut public hospital tender prices on mature medications.
Positioning
Viatris occupies an established global scale position in off-patent pharmaceuticals, supported by $8,514.0M in Developed Markets revenue and $2,332.5M in Greater China. However, high debt of $14.70B leaves it competitively constrained relative to less leveraged diversified peers like Baxter (BAX), which trades at an 11.94x forward P/E with an operating margin of 14.43%.2,3,6
Why
$17.64 (October 9, 2026)
Trim / Reduce Position
Shares trade at an 10.87% premium to our Fair value of $15.91; trim holdings on rallies.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
